Evidence map›Paper›PMID 34408275›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2022

The neurobiology of drug addiction: cross-species insights into the dysfunction and recovery of the prefrontal cortex.

Ahmet O Ceceli, Charles W Bradberry, Rita Z Goldstein

Abstract readReview
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. An emerging role for synaptic ZnPharmacology & therapeutics · 2026
    Review
  10. Article
  11. Impairment of the GABAergic system in the prefrontal cortex of male heroin addicts.European archives of psychiatry and clinical neuroscience · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmet O CeceliDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Charles W BradberryNIDA Intramural Research Program, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-2630-4144
Rita Z GoldsteinDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. rita.goldstein@mssm.edu.

Funding

Multimodal preclinical imaging studies of decisional determinants of drug vs non-drug choiceZIADA000622 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI JEDEMA, HANK · 2017 to 2025
$21.9M
Atherosclerosis in cocaine addiction: imaging risk with PET/MRR01DA049547 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Nelly Alia-Klein, Zahi A. Fayad · 2022 to 2026
$3.9M
Neuroimaging response inhibition and salience attribution changes during mindfulness-based treatment of human heroin addictionR01AT010627 · NCCIH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2019 to 2023
$3.8M
Sex differences in the neural correlates underlying impairments in response inhibition and salience attribution in cocaine addictionR01DA048301 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2020 to 2024
$3.4M
Using event-related potentials to longitudinally track cue-induced craving incubation in cocaine addicted individualsR01DA041528 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GOLDSTEIN, RITA Z · 2016 to 2020
$3.3M
Diagnostic and prognostic biomarkers for subtypes of addiction-related circuit dysfunctionR01DA047851 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI GOLDSTEIN, RITA Z, LISTON, CONOR M · 2019 to 2022
$2.4M
NCCIH NIH HHS R01 AT010627NIDA NIH HHS R01 DA041528NIDA NIH HHS R01 DA047851NIDA NIH HHS R01 DA048301NIDA NIH HHS R01 DA049547
6 · The paper itself

Abstract

A growing preclinical and clinical body of work on the effects of chronic drug use and drug addiction has extended the scope of inquiry from the putative reward-related subcortical mechanisms to higher-order executive functions as regulated by the prefrontal cortex. Here we review the neuroimaging evidence in humans and non-human primates to demonstrate the involvement of the prefrontal cortex in emotional, cognitive, and behavioral alterations in drug addiction, with particular attention to the impaired response inhibition and salience attribution (iRISA) framework. In support of iRISA, functional and structural neuroimaging studies document a role for the prefrontal cortex in assigning excessive salience to drug over non-drug-related processes with concomitant lapses in self-control, and deficits in reward-related decision-making and insight into illness. Importantly, converging insights from human and non-human primate studies suggest a causal relationship between drug addiction and prefrontal insult, indicating that chronic drug use causes the prefrontal cortex damage that underlies iRISA while changes with abstinence and recovery with treatment suggest plasticity of these same brain regions and functions. We further dissect the overlapping and distinct characteristics of drug classes, potential biomarkers that inform vulnerability and resilience, and advancements in cutting-edge psychological and neuromodulatory treatment strategies, providing a comprehensive landscape of the human and non-human primate drug addiction literature as it relates to the prefrontal cortex.

Indexed as

Prefrontal CortexSubstance-Related DisordersAnimalsBrainExecutive FunctionNeuroimaging

Identifiers

PMID34408275
PMCPMC8617203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.